Patent application number | Description | Published |
20100186375 | Layered Diesel Oxidation Catalyst Composites - Provided are diesel exhaust components where palladium is segregated from a molecular sieve, specifically a zeolite, in a catalytic material. In the catalytic material, therefore, there are at least two layers: a palladium-containing layer that is substantially free of a molecular sieve and a hydrocarbon trap layer that comprises at least one molecular sieve and is substantially free of palladium. The palladium is provided on a high surface area, porous refractory metal oxide support. The catalytic material can further comprise a platinum component, where a minor amount of the platinum component is in the hydrocarbon trap layer, and a majority amount of the platinum component is in the palladium-containing layer. Systems and methods of using the same are also provided. | 07-29-2010 |
20100251700 | HC-SCR System for Lean Burn Engines - Systems and methods for abating NOx emission in an exhaust stream are provided. Systems comprising hydrocarbon conversion over a partial oxidation catalyst in a slip stream and a hydrocarbon selective catalytic reduction catalyst are described. The emissions treatment system is advantageously used for the treatment of exhaust streams from lean burn engines including diesel engines, lean burn gasoline engines and locomotive engines. | 10-07-2010 |
20110173950 | Emissions Treatment System with Ammonia-Generating and SCR Catalysts - Provided are emissions treatment systems for an exhaust stream having an ammonia-generating component, such as a NOx storage reduction (NSR) catalyst or a lean NOx trap (LNT) catalyst, and an SCR catalyst disposed downstream of the ammonia-generating catalyst. The SCR catalyst can be a molecular sieve having the CHA crystal structure, for example SSZ-13 or SAPO-34, which can be ion-exchanged with copper. The LNT can be layered, having an undercoat washcoat layer comprising a support material, at least one precious metal, and at least one NOx sorbent selected from the group consisting of alkaline earth elements, rare earth elements, and combinations thereof and a top washcoat layer comprising a support material, at least one precious metal, and ceria in particulate form, the top washcoat layer being substantially free of alkaline earth components. The emissions treatment system is advantageously used for the treatment of exhaust streams from diesel engines and lean burn gasoline engines. | 07-21-2011 |
20140047819 | Emissions Treatment System with Ammonia-Generating and SCR Catalysts - Provided are emissions treatment systems for an exhaust stream having an ammonia-generating component, such as a NOx storage reduction (NSR) catalyst or a lean NOx trap (LNT) catalyst, and an SCR catalyst disposed downstream of the ammonia-generating catalyst. The SCR catalyst can be a molecular sieve having the CHA crystal structure, for example SSZ-13 or SAPO-34, which can be ion-exchanged with copper. The LNT can be layered, having an undercoat washcoat layer comprising a support material, at least one precious metal, and at least one NOx sorbent selected from the group consisting of alkaline earth elements, rare earth elements, and combinations thereof and a top washcoat layer comprising a support material, at least one precious metal, and ceria in particulate form, the top washcoat layer being substantially free of alkaline earth components. The emissions treatment system is advantageously used for the treatment of exhaust streams from diesel engines and lean burn gasoline engines. | 02-20-2014 |
20140248200 | Emissions Treatment System with Ammonia-Generating and SCR Catalysts - Provided are emissions treatment systems for an exhaust stream having an ammonia-generating component, such as a NOx storage reduction (NSR) catalyst or a lean NOx trap (LNT) catalyst, and an SCR catalyst disposed downstream of the ammonia-generating catalyst. The SCR catalyst can be a molecular sieve having the CHA crystal structure, for example SSZ-13 or SAPO-34, which can be ion-exchanged with copper. The LNT can be layered, having an undercoat washcoat layer comprising a support material, at least one precious metal, and at least one NOx sorbent selected from the group consisting of alkaline earth elements, rare earth elements, and combinations thereof and a top washcoat layer comprising a support material, at least one precious metal, and ceria in particulate form, the top washcoat layer being substantially free of alkaline earth components. The emissions treatment system is advantageously used for the treatment of exhaust streams from diesel engines and lean burn gasoline engines. | 09-04-2014 |
20150139874 | Lean NOx Trap Diesel Oxidation Catalyst With Hydrocarbon Storage Function - The present invention is directed to a lean NOx trap diesel oxidation catalyst for the treatment of exhaust gas emissions, such as the oxidation of unburned hydrocarbons (HC), and carbon monoxide (CO) and the trapping and reduction of nitrogen oxides (NOx). Catalytic composites can comprise a catalytic material on a carrier, the catalytic material comprising a first NOx trap layer that comprises a NOx sorbent and one or more precious metal components located on the carrier and a second NOx trap layer containing hydrocarbon trapping functionality located over the first NOx trap layer that comprises a NOx sorbent, one or more precious metal components, and a zeolite, for example a beta zeolite, wherein the zeolite is substantially free of framework aluminum. Such zeolites are characterized by high crystallinity and/or by being substantially free of framework aluminum to minimize surface acidity. | 05-21-2015 |
20150174564 | PT-PD Diesel Oxidation Catalyst With CO/HC Light-Off And HC Storage Function - A diesel oxidation catalyst for the treatment of exhaust gas emissions, such as the oxidation of unburned hydrocarbons (HC), and carbon monoxide (CO) and the reduction of nitrogen oxides (NOx) is described. More particularly, the present invention is directed to a washcoat composition comprising high silica to alumina zeolite and platinum and palladium such that the zeolite minimizes negative interactions of these platinum group metals with the zeolite. | 06-25-2015 |
Patent application number | Description | Published |
20110135706 | NERVE TREATMENT DEVICES AND METHODS - Devices and methods for treating defects in peripheral nerves are provided. The devices can include acellular arterial tissue matrices that facilitate regrowth of nerve tissue across a gap or defect in a peripheral nerve. | 06-09-2011 |
20130028984 | NATURAL TISSUE SCAFFOLDS AS TISSUE FILLERS - Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers. | 01-31-2013 |
20140186460 | Elastic Tissue Matrix Derived Hydrogel - A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided. | 07-03-2014 |
20150126453 | METHODS OF REMOVING ALPHA-GALACTOSE - Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided. | 05-07-2015 |
20150282925 | DECELLULARIZED MUSCLE MATRIX - Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can, optionally, be joined to one or more decellularized dermal matrices. The muscle implants can be used to enhance muscle volume or to treat muscle damage, defects, and/or disorders. The decellularized muscle matrices in the implants retain at least some of the myofibers found in a muscle tissue prior to processing. | 10-08-2015 |
20150283302 | Natural Tissue Scaffolds as Tissue Fillers - Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers. | 10-08-2015 |
20160090572 | Method for Enzymatic Treatment of Tissue Products - Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix. | 03-31-2016 |
Patent application number | Description | Published |
20090280160 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION - Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow for enhanced systemic delivery of therapeutically active form of phenylephrine. | 11-12-2009 |
20100081672 | PH SENSITIVE MATRIX FORMULATION - The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH sensitive polymers that are designed for accelerated hydration, expansion, disintegration and dissolution at the higher pH of the upper GI tract, thereby, ensuring that any therapeutic agent that has not been released in the stomach is released in the upper GI tract, thus maximizing absorption of therapeutic agent that has a window of absorption located at the upper GI tract. | 04-01-2010 |
20110034478 | Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs - The present invention provides a solid molecularly dispersed composition comprising a poorly water soluble and weakly basic azole antifungal compound and a pH sensitive polymer, pharmaceutical compositions, comprising the solid molecularly dispersed composition of the invention and methods of treating and/or preventing a fungal infection in a patient in need thereof comprising orally administering a pharmaceutical composition comprising a composition of the invention to a patient in need thereof. Preferably the antifungal, compound is posaconazole, and the pH sensitive polymer is HPMCAS. | 02-10-2011 |
20110038925 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 02-17-2011 |
20110123627 | HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS COMPRISING THE SAME - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material. | 05-26-2011 |
20120022032 | CORTICOSTEROID COMPOSITIONS AND METHODS OF TREATMENTS THEREOF - This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages. | 01-26-2012 |
20150150990 | ORAL PHARMACEUTICAL COMPOSITIONS IN A SOLID DISPERSION COMPRISING PREFERABLY POSACONAZOLE AND HPMCAs - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature temperature (Tg) of less than about 110° C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. | 06-04-2015 |
20160024092 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 01-28-2016 |
Patent application number | Description | Published |
20120029081 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 02-02-2012 |
20120232149 | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 09-13-2012 |
20130102675 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 04-25-2013 |
20150290147 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR COLONIC ABOSORPTION - The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma. | 10-15-2015 |
Patent application number | Description | Published |
20130303618 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 11-14-2013 |
20140163103 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 06-12-2014 |
20150094371 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 04-02-2015 |
20150352066 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 12-10-2015 |
Patent application number | Description | Published |
20100165348 | RECONSTRUCTION OF NONLINEAR WAVE PROPAGATION - Disclosed are systems and methods for characterizing a nonlinear propagation environment by numerically propagating a measured output waveform resulting from a known input waveform. The numerical propagation reconstructs the input waveform, and in the process, the nonlinear environment is characterized. In certain embodiments, knowledge of the characterized nonlinear environment facilitates determination of an unknown input based on a measured output. Similarly, knowledge of the characterized nonlinear environment also facilitates formation of a desired output based on a configurable input. In both situations, the input thus characterized and the output thus obtained include features that would normally be lost in linear propagations. Such features can include evanescent waves and peripheral waves, such that an image thus obtained are inherently wide-angle, farfield form of microscopy. | 07-01-2010 |
20140016183 | RECONSTRUCTION OF NONLINEAR WAVE PROPAGATION - Disclosed are systems and methods for characterizing a nonlinear propagation environment by numerically propagating a measured output waveform resulting from a known input waveform. The numerical propagation reconstructs the input waveform, and in the process, the nonlinear environment is characterized. In certain embodiments, knowledge of the characterized nonlinear environment facilitates determination of an unknown input based on a measured output. Similarly, knowledge of the characterized nonlinear environment also facilitates formation of a desired output based on a configurable input. In both situations, the input thus characterized and the output thus obtained include features that would normally be lost in linear propagations. Such features can include evanescent waves and peripheral waves, such that an image thus obtained are inherently wide-angle, farfield form of microscopy. | 01-16-2014 |